Latest Biotech News

FDA greenlit AbbVie’s next-generation dopamine agonist, tavapadon, branded as Juvmo, for Parkinson’s symptom relief—positioning it as a next-step alternative to existing dopamine-therapy options...

A U.S. jury awarded Nektar Therapeutics $90 million in its dispute with Eli Lilly over development of the autoimmune disease therapy rezpegaldesleukin (rezpeg). The verdict concluded Lilly...

Multiple new cancer findings sharpen how therapies may be matched to biology—ranging from drug-resistance mechanisms to next-wave combination strategies. In breast cancer, researchers reported a...

Cellular therapies continued to evolve with new clinical and engineering directions. A landmark German trial tested a digital care model to better manage the post-treatment phase in 306 cell...

Biotech finance stayed active as companies pursued public-market entry and large strategic capital moves. ADARx Pharmaceuticals priced a $446.3 million IPO, expanding cash for its RNA-silencing...

Efforts to keep pace with antimicrobial resistance and improve detection moved forward on several fronts. A new study reported a rapid fluorescence PCR approach to spot macrolide-resistant...

Biomarker discovery and AI-assisted prediction continued to focus on practical decision points in oncology. A new study proposed a simple blood formula to predict survival in colorectal cancer...

Genome and gene-silencing platforms moved from concept to clearer clinical footing. Prime Medicine received FDA IND approval for PM-647, an in vivo Prime Editor targeting α-1 antitrypsin...

New research deepened depression biology and aimed at more scalable screening approaches. Scientists reported a stress-triggered molecular switch that drives depression, adding a mechanistic lead...

Early clinical signals emerged from solid-tumor strategy testing. An oral Wnt-blocking pill combined with lenvatinib showed durable tumor shrinkage in women with advanced endometrial cancer after...

FDA cleared AbbVie’s next-generation dopamine agonist tavapadon for Parkinson’s disease, with the drug to be branded as Juvmo. The approval positions tavapadon as a successor to existing...

Novo Nordisk agreed to a global exclusive license for Nanexa’s drug delivery technology in a deal valued up to about €1.165 billion (US$1.325 billion). The collaboration is aimed at improving...

A U.S. jury awarded Nektar Therapeutics $90 million in damages in its dispute with Eli Lilly over a fractured licensing arrangement for rezpegaldesleukin (rezpeg). The verdict followed a contract...

ADARx Pharmaceuticals launched in a stock-market debut centered on RNAi therapeutics, raising $446.3 million and valuing the company north of $1.8 billion after upsizing demand-led terms. The IPO...

A landmark German trial is testing a digital care model designed to evaluate and support patients undergoing cellular therapies. The study will put 306 patients to the test, focusing on...

An experimental approach combining oral Wnt-blocking therapy with lenvatinib showed durable tumor shrinkage in advanced endometrial cancer after immunotherapy and chemotherapy failure. The results...

New data from Jordan’s national surveillance suggests carbapenem resistance is widespread in Gram-negative ICU infections. The study reports that more than one in three Gram-negative infections in...

A simplified blood-based marker approach may help clinicians predict survival in colorectal cancer patients whose disease spreads to the lungs. The study describes a “simple blood formula” aimed...

A Nature study identified a ferroptosis control switch centered on the fission protein MFF, linking organelle dynamics to an iron-dependent cell death program. The finding positions ferroptosis...

A large investigation found that many patients receiving lifesaving cellular therapies experience hidden blood pressure drops. The study reported that more than half of patients develop...